# Revelation (REVB) — News REVB · NASDAQ · Stock Canonical page: https://www.lighthorse.io/tickers/revb/news ## Recent headlines - [Wipro exec on Perm - Did not file for permanent labor certification in last 3 years](https://www.ainvest.com/news/wipro-exec-perm-file-permanent-labor-certification-3-years-2610) — AInvest Wire, Oct 15, 2026 Wipro, a global information technology services company, recently disclosed that it did not file for permanent labor certification for foreign workers in the past three years, according to an executive statement. This revelation comes amid ongoing regulatory scrutiny and evolving immigration… - [Georgieva: We need to move 'debt obstacle' for Senegal](https://www.ainvest.com/news/georgieva-move-debt-obstacle-senegal-2610) — AInvest Wire, Oct 14, 2026 International Monetary Fund (IMF) Managing Director Kristalina Georgieva has emphasized the urgent need to address the "debt obstacle" facing Senegal, as the West African nation grapples with a significant financial crisis. Recent audits have revealed that debt-to-GDP ratio may be as high as 119%,… - [Celsius Resources Ltd: Complaint alleges Chalmers concealed Sodor's inability to pay for MMCI shares and no intention to relinquish them](https://www.ainvest.com/news/celsius-resources-complaint-alleges-chalmers-concealed-sodor-inability-pay-mmci-shares-intention-relinquish-2610) — AInvest Wire, Oct 8, 2026 A recent legal filing alleges that Celsius Resources Ltd. CEO, Chalmers, concealed critical information regarding the company's financial obligations and intentions concerning MMCI shares. Specifically, the complaint claims that Chalmers failed to disclose that Sodor, a related entity, was unable… - [Revelation Biosciences - Phase 2/3 Titan study expected to begin later this year](https://www.ainvest.com/news/revelation-biosciences-phase-2-3-titan-study-expected-year-2608) — AInvest Wire, Aug 19, 2026 Revelation Biosciences, Inc. (NASDAQ: REVB) is preparing to initiate its Phase 2/3 Titan study later in 2026, following the successful completion of its PRIME Phase 1b clinical trial in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). The PRIME study, which concluded in July 2025,… - [Optronics Systems - Karen Hawkins to resign as CFO and secretary effective December 31, 2026 - SEC filing](https://www.ainvest.com/news/optronics-systems-karen-hawkins-resign-cfo-secretary-effective-december-31-2026-sec-filing-2606) — AInvest Wire, Jun 17, 2026 Optex Systems Holdings Inc. has announced that Karen Hawkins will resign from her roles as Chief Financial Officer and Secretary of the company, effective December 31, 2026, as disclosed in a recent SEC filing . The resignation follows a routine executive transition and is not attributed to any… --- Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express. This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness. Data provided by [AInvest](https://www.ainvest.com).